Plasma C1q/TNF-Related Protein-9 Levels Are Associated with Atherosclerosis in Patients with Type 2 Diabetes without Renal Dysfunction

Asada, Mariko; Morioka, Tomoaki; Yamazaki, Yuko; Kakutani, Yoshinori; Kawarabayashi, Reina; Motoyama, Koka; Mori, Katsuhito; Fukumoto, Shinya; Shioi, Atsushi; Shoji, Tetsuo; Emoto, Masanori; Inaba, Masaaki

doi:10.1155/2016/8624313

Cited by 17 publications

(17 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, a PPAR-agonist could affect the expression of CTRP9 [ 27 ] and, therefore, patients treated with this drug (agonist) were excluded from the study. The results of this study were in line with those of Chang Hee Jung et al, who reported a positive association of CTRP9 levels with BMI and arterial stiffness [ 19 ] and a study by Asada et al in which a positive association between serum CTRP9 levels and atherosclerosis in T2DM patients was demonstrated [ 18 ]. In contrast, decreased and increased levels of circulating CTRP9 after bariatric surgery and in patients with impaired fasting glucose were shown, respectively [ 20 ], as well as increased serum CTRP9 levels in newly diagnosed T2DM patients [ 28 ].…”

Section: Discussionsupporting

confidence: 91%

“…These results indicate that serum levels of CTRP9 were elevated in CAD and T2DM patients. Preceding studies showed increased levels of serum CTRP9 in obesity and its attendant health risks [ 8 , 18 – 20 ], while decreased serum levels of CTRP9 was reported in CAD patients [ 16 ]. These observed discrepancies may have resulted from differences such as non-CAD subject selection/exclusion criteria and ethnicities between studies.…”

Section: Discussionmentioning

confidence: 99%

“…It has higher vasoactive potency than adiponectin [ 12 ], has a protective role in remodeling after acute myocardial infarction [ 13 ], decreases inflammation [ 14 ] and inhibits vascular smooth muscle cell proliferation [ 15 ]. The association of plasma CTRP9 levels with atherosclerosis has been suggested by several lines of evidence [ 16 – 18 ]. For instance, Chang Hee Jung et al reported independent association between CTRP9 and arterial stiffness [ 19 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Association of circulating CTRP9 with soluble adhesion molecules and inflammatory markers in patients with type 2 diabetes mellitus and coronary artery disease

et al. 2018

View full text Add to dashboard Cite

C1q/TNF-related protein 9 (CTRP9) is a paralogue of adiponectin with known favorable effects on lipid and glucose metabolism. A potential role of CTRP9 for regulation of endothelium function has been suggested by previous studies. However, no studies have examined the relation between serum CTRP9 levels and adhesion molecules in patients with type 2 diabetes mellitus (T2DM) and coronary artery disease (CAD). The present study was conducted on 337 subjects who underwent coronary angiography and were categorized into four groups according to the presence of CAD and T2DM (control, CAD, T2DM and CAD+T2DM). Serum levels of CTRP9, adiponectin, sICAM-1, sVCAM-1, sE-Selectin, IL-6 and TNF-α were measured. It was found that the circulating CTRP9 levels were independently associated with increased risk of CAD and T2DM in addition to elevated levels of serum CTRP9 in CAD, T2DM and CAD+T2DM groups. A significant association of serum CTRP9 levels with adhesion molecules in CAD and T2DM patients as well as serum TNF-α levels in CAD individuals was noted. A significant relation between the circulating levels of CTRP9 and HOMA-IR in T2DM subjects was also observed. The results revealed increased circulating levels of CTRP9 in T2DM and CAD individuals which suggests a compensatory response to insulin resistance, inflammatory milieu and endothelial dysfunction; however, more studies are needed to confirm this.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Association of circulating CTRP9 with soluble adhesion molecules and inflammatory markers in patients with type 2 diabetes mellitus and coronary artery disease

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The mean IMT of the common carotid artery (CCA) was measured by using a phase-locked echo-tracking system, which was equipped with a high-resolution real-time 13 MHz linear scanner (Prosound SSD 6500 and F75; Hitachi Aloka Medical, Ltd., Tokyo, Japan), as previously described [25]. The IMT value was determined by using a measurement software (Intimascope; Media Cross Co. Ltd, Tokyo, Japan), as described elsewhere [25, 26]. In brief, images were obtained 20 mm proximal to the origin of the bulb at the far wall of both CCAs.…”

Section: Methodsmentioning

confidence: 99%

Plasma omentin levels are inversely associated with atherosclerosis in type 2 diabetes patients with increased plasma adiponectin levels: a cross-sectional study

Nishimura

Morioka

Hayashi

et al. 2019

Cardiovasc Diabetol

Self Cite

View full text Add to dashboard Cite

BackgroundOmentin and adiponectin are among the anti-inflammatory and anti-atherogenic adipokines that have potentially beneficial effects on cardiovascular disorders. Recent studies indicate a paradoxical relationship between adiponectin and cardiovascular mortality across many clinical settings including type 2 diabetes. In this study, we characterized the clinical features of type 2 diabetes patients with increased adiponectin levels and examined the association between omentin and atherosclerosis in those patients.MethodsThe subjects were 413 patients with type 2 diabetes. Fasting plasma omentin and total adiponectin levels were measured by enzyme-linked immunosorbent assay. The intima-media thickness (IMT) of the common carotid artery was measured by ultrasonography. The subjects were stratified according to the median value of plasma adiponectin.ResultsIn high-adiponectin group, omentin levels were higher, while IMT tended to be greater than those in low-adiponectin group. The high-adiponectin group also exhibited older age, higher systolic blood pressure, lower kidney function, body mass index, and insulin resistance index compared to the low-adiponectin group. Multivariate analysis revealed that omentin levels were independently and negatively associated with IMT in high-adiponectin group, but not in low-adiponectin group, after adjusting for adiponectin levels and traditional cardiovascular risk factors. On the other hand, adiponectin levels were not significantly associated with IMT in either group.ConclusionsPlasma omentin levels are inversely associated with IMT in type 2 diabetes patients with increased adiponectin levels and multiple cardiovascular risk factors. This study suggests a protective role of omentin against atherosclerosis in type 2 diabetes patients, which is potentially influenced by adiponectin level and cardiovascular risk status.

show abstract

“…Clinical studies showed significantly lower CTRP9 expression levels in patients with CAD with or without pulmonary arterial hypertension (Li et al, ; Wang et al, ) whose major pathological change is vascular remodeling as well. Nevertheless, other researchers found that circulating levels of CTRP9 increased in CAD with or without T2DM individuals (Moradi et al, ) and were positively correlated with carotid intima‐media thickness (IMT) and arterial stiffness (Asada et al, ; Audette, Challis, Jones, Sibley, & Matthews, ). Remodeling is an active process of vascular structure changes, involving cell growth, death, migration, as well as the extracellular matrix production and degradation.…”

Section: Introductionmentioning

confidence: 99%

C1q/TNF‐related protein 9: A novel therapeutic target in ischemic stroke?

Yang

Fan

Sawmiller

et al. 2018

J of Neuroscience Research

View full text Add to dashboard Cite

| INTRODUC TI ONIschemic stroke and coronary atherosclerosis disease (CAD) are both kinds of atherosclerotic diseases with high morbidity and high mortality, which have already been on the spotlight in both clinic and research. Vascular lesion is the major feature in the pathogenesis of these two diseases. Initially, the endothelial cells (EC) are damaged by risk factors, followed with activated platelets, inflammatory reactions, and accelerated vessel wall remodeling. Consequently, atherosclerotic plaques forming, rupture and erosion, with different subtypes of surface thrombosis, vasospasm and distal vascular embolization, lead to ischemic lesions, including ischemic stroke and CAD. However, the molecular mechanism of vascular lesion is complicated, which requires further research for the full understanding of pathogenesis of atherosclerotic diseases.C1q/TNF-related protein 9 (CTRP9) is a newly discovered adipokine. By searching databases of Medline and Web of Science (WOS), we found only a few reports about this factor, most of which were published in the past two years. Meanwhile, they mainly expounded the role of CTRP9 in the blood vessels related pathogenesis of CAD, including regulating energy metabolism, modulating vasomotion, protecting EC, inhibiting platelet activation, inhibiting pathological vascular remodeling, stabilizing atherosclerotic plaques, and protecting heart. Here, we reviewed the genic features, proteinic features and physiologic functions of CTRP9, and proposed some possible associations between CTRP9 and ischemic stroke as well. AbstractIschemic stroke has become a serious public health problem, which is in need of advanced research on the prevention and treatment. As a newly discovered adipokine, C1q/TNF-related protein 9 (CTRP9) plays a vital role in the pathogenesis of coronary atherosclerosis disease (CAD), including regulating energy metabolism, modulating vasomotion, protecting endothelial cells, inhibiting platelet activation, inhibiting pathological vascular remodeling, stabilizing atherosclerotic plaques, and protecting heart. The present review raised a critical question of whether CTRP9 could also have the capacity of protecting the brain tissue and decreasing the severity of brain lesions in the ischemic stroke since CAD and ischemic stroke are both the major subtypes of atherosclerotic vascular diseases which share a large of common pathogenesis in the vascular lesion particularly. Therefore, we proposed that CTRP9 could be a feasible biomarker and potential therapeutic target in ischemic stroke on the basis of the reviewed research reports. K E Y W O R D Sadipokine, coronary atherosclerosis disease, CTRP9, ischemic stroke | 129 YANG et al.

show abstract

Plasma C1q/TNF-Related Protein-9 Levels Are Associated with Atherosclerosis in Patients with Type 2 Diabetes without Renal Dysfunction

Cited by 17 publications

References 40 publications

Association of circulating CTRP9 with soluble adhesion molecules and inflammatory markers in patients with type 2 diabetes mellitus and coronary artery disease

Association of circulating CTRP9 with soluble adhesion molecules and inflammatory markers in patients with type 2 diabetes mellitus and coronary artery disease

Plasma omentin levels are inversely associated with atherosclerosis in type 2 diabetes patients with increased plasma adiponectin levels: a cross-sectional study

C1q/TNF‐related protein 9: A novel therapeutic target in ischemic stroke?

Contact Info

Product

Resources

About